NEW YORK (GenomeWeb) – N-of-One said today that it will provide clinical interpretation services to Intermountain Healthcare as part of the hospital system's oncology precision medicine services program.

Under the terms of the agreement, N-of-One will handle the interpretation of cancer patients' next-generation sequencing test results. Using its platform, the firm will link relevant biological and clinical knowledge to the mutation profiles of tumors and help oncologists identify more effective therapeutic strategies for their patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.